CDMO WuXi STA opens manufacturing facility to produce oligonucleotides
CDMO WuXi STA is building out its manufacturing site in Changzhou, China in stages. Its newest milestone is a large-scale oligonucleotide API manufacturing unit.
It says the 30,000-square-foot manufacturing facility can produce a variety of oligonucleotides including DNA, RNA, morpholino oligonucleotide (PMO) and peptide conjugates (PPMO). It can produce oligonucleotide APIs up to 1 mol per synthesis run.
“The opening of this large-scale manufacturing facility will empower more global partners to expedite the development and commercialization of oligonucleotide drugs to benefit patients worldwide," WuXi STA CEO Minzhang Chen said in a statement.
Roche recently paid Dicerna Pharmaceuticals $200 million (€179 million) upfront for a global license to an RNAi drug targeted at hepatitis B. The deal could reach $1.5 billion in milestones as the two collaborate on other hepatitis B virus (HBV) assets. Allergan recently paid $25 million to Exicure to discover nucleic acid hair loss drugs.
WuXi STA’s Changzhou site officially opened in March 2016 with a 10,000-square-meter facility. When complete, the CDMO says it will house more than 500 scientists and 1,500 cubic meters of reactor volume.
Jan 3, 2020
https://www.fiercepharma.com/
